Clinical impact of suboptimal RAASi therapy following an episode of hyperkalemia

Figures

• 

  Fig. 1. Attainment of guideline-recommended RAASi dose in (a) the US and (b) Japan. HK hyperkalemia, mo month, RAASi renin-angiotensin-aldosterone system inhibitor

• 

  Fig. 2. RAASi change following an HK episode in (a) the US and (b) Japan. ACEi angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blocker, ARNi angiotensin receptor-neprilysin inhibitor, HK hyperkalemia, MRA mineralocorticoid receptor antagonist, RAASi renin-angiotensin-aldosterone system inhibitor

• 

  Fig. 3. Risk of cardiorenal composite outcome by change in RAASi treatment following HK episode: (a) the US, (b) Japan. CI confidence interval, HK hyperkalemia, RAASi renin-angiotensin-aldosterone system inhibitor. P-value for the differences between the groups: US, p < 0.001; Japan, p < 0.001